nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—COMT—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0255	0.103	CbGpPWpGaD
Methyldopa—DDC—Dopamine metabolism—NQO1—urinary bladder cancer	0.0144	0.0582	CbGpPWpGaD
Methyldopa—DDC—renal system—urinary bladder cancer	0.0133	0.0879	CbGeAlD
Methyldopa—COMT—prostate gland—urinary bladder cancer	0.0129	0.0853	CbGeAlD
Methyldopa—COMT—Dopamine metabolism—NQO1—urinary bladder cancer	0.0128	0.0517	CbGpPWpGaD
Methyldopa—DDC—Dopaminergic Neurogenesis—GLI1—urinary bladder cancer	0.0126	0.0511	CbGpPWpGaD
Methyldopa—COMT—seminal vesicle—urinary bladder cancer	0.0109	0.0722	CbGeAlD
Methyldopa—SLC15A1—epithelium—urinary bladder cancer	0.0107	0.0705	CbGeAlD
Methyldopa—DDC—female reproductive system—urinary bladder cancer	0.0107	0.0704	CbGeAlD
Methyldopa—SLC15A1—renal system—urinary bladder cancer	0.00991	0.0654	CbGeAlD
Methyldopa—COMT—Estrogen metabolism—NQO1—urinary bladder cancer	0.00984	0.0398	CbGpPWpGaD
Methyldopa—COMT—smooth muscle tissue—urinary bladder cancer	0.00915	0.0604	CbGeAlD
Methyldopa—COMT—renal system—urinary bladder cancer	0.00881	0.0581	CbGeAlD
Methyldopa—COMT—urethra—urinary bladder cancer	0.00865	0.0571	CbGeAlD
Methyldopa—COMT—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00826	0.0334	CbGpPWpGaD
Methyldopa—COMT—Phase II conjugation—GSTO2—urinary bladder cancer	0.00783	0.0317	CbGpPWpGaD
Methyldopa—COMT—Phase II conjugation—NAT1—urinary bladder cancer	0.00783	0.0317	CbGpPWpGaD
Methyldopa—COMT—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00754	0.0305	CbGpPWpGaD
Methyldopa—SLC15A1—vagina—urinary bladder cancer	0.00718	0.0474	CbGeAlD
Methyldopa—COMT—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00716	0.029	CbGpPWpGaD
Methyldopa—COMT—female reproductive system—urinary bladder cancer	0.00706	0.0466	CbGeAlD
Methyldopa—ADRA2A—prostate gland—urinary bladder cancer	0.00658	0.0434	CbGeAlD
Methyldopa—Aminosalicylic Acid—MPO—urinary bladder cancer	0.00653	0.285	CrCbGaD
Methyldopa—COMT—vagina—urinary bladder cancer	0.00638	0.0421	CbGeAlD
Methyldopa—DDC—lymph node—urinary bladder cancer	0.00624	0.0412	CbGeAlD
Methyldopa—ADRA2A—seminal vesicle—urinary bladder cancer	0.00557	0.0367	CbGeAlD
Methyldopa—Mesalazine—MPO—urinary bladder cancer	0.00513	0.224	CrCbGaD
Methyldopa—DDC—Amino acid and derivative metabolism—GSTZ1—urinary bladder cancer	0.00507	0.0205	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—GSTZ1—urinary bladder cancer	0.00483	0.0196	CbGpPWpGaD
Methyldopa—DDC—Parkinsons Disease Pathway—CCNE1—urinary bladder cancer	0.00481	0.0195	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00476	0.0193	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—GSTO2—urinary bladder cancer	0.00458	0.0185	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—NAT1—urinary bladder cancer	0.00458	0.0185	CbGpPWpGaD
Methyldopa—Mesalazine—PPARG—urinary bladder cancer	0.00455	0.199	CrCbGaD
Methyldopa—COMT—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00452	0.0183	CbGpPWpGaD
Methyldopa—ADRA2A—urethra—urinary bladder cancer	0.00441	0.0291	CbGeAlD
Methyldopa—COMT—Phase II conjugation—NAT2—urinary bladder cancer	0.00429	0.0174	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—UGT2B7—urinary bladder cancer	0.00419	0.017	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00413	0.0167	CbGpPWpGaD
Methyldopa—COMT—lymph node—urinary bladder cancer	0.00413	0.0272	CbGeAlD
Methyldopa—DDC—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.00387	0.0157	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—CYP4B1—urinary bladder cancer	0.00377	0.0153	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00372	0.0151	CbGpPWpGaD
Methyldopa—ADRA2A—female reproductive system—urinary bladder cancer	0.00359	0.0237	CbGeAlD
Methyldopa—COMT—Phase II conjugation—HPGDS—urinary bladder cancer	0.00343	0.0139	CbGpPWpGaD
Methyldopa—COMT—Phase II conjugation—GSTT1—urinary bladder cancer	0.00333	0.0135	CbGpPWpGaD
Methyldopa—ADRA2A—vagina—urinary bladder cancer	0.00325	0.0214	CbGeAlD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00268	0.0108	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—NAT2—urinary bladder cancer	0.00251	0.0102	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00247	0.01	CbGpPWpGaD
Methyldopa—Aminosalicylic Acid—PTGS2—urinary bladder cancer	0.00245	0.107	CrCbGaD
Methyldopa—Epinephrine—TNF—urinary bladder cancer	0.00233	0.102	CrCbGaD
Methyldopa—COMT—Phase II conjugation—GSTP1—urinary bladder cancer	0.00231	0.00933	CbGpPWpGaD
Methyldopa—COMT—Phase II conjugation—GSTM1—urinary bladder cancer	0.00212	0.00857	CbGpPWpGaD
Methyldopa—ADRA2A—lymph node—urinary bladder cancer	0.0021	0.0139	CbGeAlD
Methyldopa—COMT—Biological oxidations—HPGDS—urinary bladder cancer	0.00201	0.00812	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00195	0.00791	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—GSTT1—urinary bladder cancer	0.00195	0.00788	CbGpPWpGaD
Methyldopa—Mesalazine—PTGS2—urinary bladder cancer	0.00192	0.0839	CrCbGaD
Methyldopa—Infestation—Etoposide—urinary bladder cancer	0.00192	0.00331	CcSEcCtD
Methyldopa—Bradycardia—Cisplatin—urinary bladder cancer	0.00191	0.00331	CcSEcCtD
Methyldopa—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.00187	0.00323	CcSEcCtD
Methyldopa—Jaundice—Etoposide—urinary bladder cancer	0.00187	0.00323	CcSEcCtD
Methyldopa—Leukopenia—Thiotepa—urinary bladder cancer	0.00187	0.00323	CcSEcCtD
Methyldopa—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.00185	0.00319	CcSEcCtD
Methyldopa—Colitis—Epirubicin—urinary bladder cancer	0.00184	0.00319	CcSEcCtD
Methyldopa—Gynaecomastia—Methotrexate—urinary bladder cancer	0.00184	0.00317	CcSEcCtD
Methyldopa—Angiopathy—Gemcitabine—urinary bladder cancer	0.00183	0.00316	CcSEcCtD
Methyldopa—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00182	0.00314	CcSEcCtD
Methyldopa—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.00181	0.00313	CcSEcCtD
Methyldopa—Agranulocytosis—Etoposide—urinary bladder cancer	0.00179	0.00309	CcSEcCtD
Methyldopa—Hepatocellular injury—Doxorubicin—urinary bladder cancer	0.00178	0.00307	CcSEcCtD
Methyldopa—Arthralgia—Thiotepa—urinary bladder cancer	0.00178	0.00307	CcSEcCtD
Methyldopa—Myalgia—Thiotepa—urinary bladder cancer	0.00178	0.00307	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00176	0.00305	CcSEcCtD
Methyldopa—Cardiac disorder—Cisplatin—urinary bladder cancer	0.00174	0.00301	CcSEcCtD
Methyldopa—Colitis—Doxorubicin—urinary bladder cancer	0.00171	0.00295	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—NQO1—urinary bladder cancer	0.0017	0.00686	CbGpPWpGaD
Methyldopa—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00169	0.00293	CcSEcCtD
Methyldopa—Infection—Thiotepa—urinary bladder cancer	0.00169	0.00292	CcSEcCtD
Methyldopa—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00167	0.00289	CcSEcCtD
Methyldopa—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00167	0.00288	CcSEcCtD
Methyldopa—Skin disorder—Thiotepa—urinary bladder cancer	0.00165	0.00286	CcSEcCtD
Methyldopa—Flatulence—Cisplatin—urinary bladder cancer	0.00161	0.00279	CcSEcCtD
Methyldopa—Cardiac disorder—Etoposide—urinary bladder cancer	0.0016	0.00276	CcSEcCtD
Methyldopa—Leukopenia—Gemcitabine—urinary bladder cancer	0.00157	0.00271	CcSEcCtD
Methyldopa—Angiopathy—Etoposide—urinary bladder cancer	0.00156	0.0027	CcSEcCtD
Methyldopa—Eczema—Epirubicin—urinary bladder cancer	0.00155	0.00268	CcSEcCtD
Methyldopa—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00155	0.00268	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00155	0.00268	CcSEcCtD
Methyldopa—Leukopenia—Fluorouracil—urinary bladder cancer	0.00154	0.00267	CcSEcCtD
Methyldopa—Cardiac failure congestive—Epirubicin—urinary bladder cancer	0.00154	0.00266	CcSEcCtD
Methyldopa—Paraesthesia—Thiotepa—urinary bladder cancer	0.00153	0.00264	CcSEcCtD
Methyldopa—Arthralgia—Gemcitabine—urinary bladder cancer	0.00149	0.00258	CcSEcCtD
Methyldopa—Myalgia—Gemcitabine—urinary bladder cancer	0.00149	0.00258	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00148	0.00256	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00147	0.00254	CcSEcCtD
Methyldopa—Myalgia—Fluorouracil—urinary bladder cancer	0.00147	0.00254	CcSEcCtD
Methyldopa—Leukopenia—Cisplatin—urinary bladder cancer	0.00146	0.00253	CcSEcCtD
Methyldopa—Constipation—Thiotepa—urinary bladder cancer	0.00146	0.00252	CcSEcCtD
Methyldopa—Eczema—Doxorubicin—urinary bladder cancer	0.00144	0.00248	CcSEcCtD
Methyldopa—Oedema—Gemcitabine—urinary bladder cancer	0.00143	0.00247	CcSEcCtD
Methyldopa—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.00142	0.00246	CcSEcCtD
Methyldopa—Infection—Gemcitabine—urinary bladder cancer	0.00142	0.00246	CcSEcCtD
Methyldopa—Oedema—Fluorouracil—urinary bladder cancer	0.00141	0.00243	CcSEcCtD
Methyldopa—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.0014	0.00243	CcSEcCtD
Methyldopa—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.0014	0.00242	CcSEcCtD
Methyldopa—Infection—Fluorouracil—urinary bladder cancer	0.0014	0.00242	CcSEcCtD
Methyldopa—Myalgia—Cisplatin—urinary bladder cancer	0.00139	0.00241	CcSEcCtD
Methyldopa—Skin disorder—Gemcitabine—urinary bladder cancer	0.00139	0.0024	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00138	0.00239	CcSEcCtD
Methyldopa—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00138	0.00239	CcSEcCtD
Methyldopa—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00138	0.00238	CcSEcCtD
Methyldopa—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.00138	0.00238	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00136	0.0055	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—GSTP1—urinary bladder cancer	0.00135	0.00546	CbGpPWpGaD
Methyldopa—Breast disorder—Methotrexate—urinary bladder cancer	0.00135	0.00233	CcSEcCtD
Methyldopa—Body temperature increased—Thiotepa—urinary bladder cancer	0.00135	0.00233	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00134	0.00232	CcSEcCtD
Methyldopa—Leukopenia—Etoposide—urinary bladder cancer	0.00134	0.00232	CcSEcCtD
Methyldopa—Oedema—Cisplatin—urinary bladder cancer	0.00133	0.00231	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00133	0.00538	CbGpPWpGaD
Methyldopa—Infection—Cisplatin—urinary bladder cancer	0.00133	0.00229	CcSEcCtD
Methyldopa—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00131	0.00226	CcSEcCtD
Methyldopa—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00131	0.00226	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.0013	0.00225	CcSEcCtD
Methyldopa—Skin disorder—Cisplatin—urinary bladder cancer	0.0013	0.00224	CcSEcCtD
Methyldopa—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.00129	0.00223	CcSEcCtD
Methyldopa—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00129	0.00222	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00128	0.00222	CcSEcCtD
Methyldopa—Eosinophilia—Methotrexate—urinary bladder cancer	0.00128	0.0022	CcSEcCtD
Methyldopa—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00127	0.0022	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00127	0.00219	CcSEcCtD
Methyldopa—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00126	0.00219	CcSEcCtD
Methyldopa—Pancreatitis—Methotrexate—urinary bladder cancer	0.00126	0.00218	CcSEcCtD
Methyldopa—Breast disorder—Epirubicin—urinary bladder cancer	0.00126	0.00218	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00126	0.00217	CcSEcCtD
Methyldopa—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00125	0.00217	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—TYMS—urinary bladder cancer	0.00125	0.00505	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—GSTM1—urinary bladder cancer	0.00124	0.00502	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00124	0.00214	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.00123	0.00499	CbGpPWpGaD
Methyldopa—Constipation—Gemcitabine—urinary bladder cancer	0.00122	0.00212	CcSEcCtD
Methyldopa—Pancytopenia—Methotrexate—urinary bladder cancer	0.00122	0.00211	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00122	0.00495	CbGpPWpGaD
Methyldopa—Asthenia—Thiotepa—urinary bladder cancer	0.00122	0.00211	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00122	0.0021	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00122	0.0021	CcSEcCtD
Methyldopa—Infection—Etoposide—urinary bladder cancer	0.00121	0.0021	CcSEcCtD
Methyldopa—Abdominal distension—Epirubicin—urinary bladder cancer	0.00121	0.0021	CcSEcCtD
Methyldopa—Paraesthesia—Cisplatin—urinary bladder cancer	0.0012	0.00207	CcSEcCtD
Methyldopa—Thrombocytopenia—Etoposide—urinary bladder cancer	0.0012	0.00207	CcSEcCtD
Methyldopa—Eosinophilia—Epirubicin—urinary bladder cancer	0.00119	0.00206	CcSEcCtD
Methyldopa—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.00119	0.00206	CcSEcCtD
Methyldopa—Skin disorder—Etoposide—urinary bladder cancer	0.00119	0.00205	CcSEcCtD
Methyldopa—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00119	0.00205	CcSEcCtD
Methyldopa—Pancreatitis—Epirubicin—urinary bladder cancer	0.00118	0.00204	CcSEcCtD
Methyldopa—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00118	0.00204	CcSEcCtD
Methyldopa—Angina pectoris—Epirubicin—urinary bladder cancer	0.00117	0.00203	CcSEcCtD
Methyldopa—Breast disorder—Doxorubicin—urinary bladder cancer	0.00117	0.00202	CcSEcCtD
Methyldopa—Diarrhoea—Thiotepa—urinary bladder cancer	0.00116	0.00201	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00116	0.00201	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00115	0.00199	CcSEcCtD
Methyldopa—Infestation NOS—Methotrexate—urinary bladder cancer	0.00115	0.00198	CcSEcCtD
Methyldopa—Infestation—Methotrexate—urinary bladder cancer	0.00115	0.00198	CcSEcCtD
Methyldopa—Pancytopenia—Epirubicin—urinary bladder cancer	0.00114	0.00198	CcSEcCtD
Methyldopa—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00113	0.00196	CcSEcCtD
Methyldopa—Dizziness—Thiotepa—urinary bladder cancer	0.00113	0.00195	CcSEcCtD
Methyldopa—Abdominal distension—Doxorubicin—urinary bladder cancer	0.00112	0.00194	CcSEcCtD
Methyldopa—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00111	0.00192	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—FAS—urinary bladder cancer	0.0011	0.00447	CbGpPWpGaD
Methyldopa—Eosinophilia—Doxorubicin—urinary bladder cancer	0.0011	0.00191	CcSEcCtD
Methyldopa—Paraesthesia—Etoposide—urinary bladder cancer	0.0011	0.0019	CcSEcCtD
Methyldopa—Weight increased—Epirubicin—urinary bladder cancer	0.0011	0.0019	CcSEcCtD
Methyldopa—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00109	0.00189	CcSEcCtD
Methyldopa—Angina pectoris—Doxorubicin—urinary bladder cancer	0.00109	0.00188	CcSEcCtD
Methyldopa—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00109	0.00188	CcSEcCtD
Methyldopa—Vomiting—Thiotepa—urinary bladder cancer	0.00108	0.00187	CcSEcCtD
Methyldopa—Infestation NOS—Epirubicin—urinary bladder cancer	0.00107	0.00186	CcSEcCtD
Methyldopa—Infestation—Epirubicin—urinary bladder cancer	0.00107	0.00186	CcSEcCtD
Methyldopa—Rash—Thiotepa—urinary bladder cancer	0.00107	0.00186	CcSEcCtD
Methyldopa—Dermatitis—Thiotepa—urinary bladder cancer	0.00107	0.00185	CcSEcCtD
Methyldopa—Agranulocytosis—Methotrexate—urinary bladder cancer	0.00107	0.00185	CcSEcCtD
Methyldopa—Headache—Thiotepa—urinary bladder cancer	0.00107	0.00184	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—urinary bladder cancer	0.00106	0.00183	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00106	0.00182	CcSEcCtD
Methyldopa—Body temperature increased—Cisplatin—urinary bladder cancer	0.00105	0.00182	CcSEcCtD
Methyldopa—Jaundice—Epirubicin—urinary bladder cancer	0.00105	0.00181	CcSEcCtD
Methyldopa—Constipation—Etoposide—urinary bladder cancer	0.00105	0.00181	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.00104	0.00421	CbGpPWpGaD
Methyldopa—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00104	0.00179	CcSEcCtD
Methyldopa—Hepatitis—Methotrexate—urinary bladder cancer	0.00103	0.00178	CcSEcCtD
Methyldopa—Asthenia—Gemcitabine—urinary bladder cancer	0.00103	0.00178	CcSEcCtD
Methyldopa—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00102	0.00176	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—urinary bladder cancer	0.00101	0.00175	CcSEcCtD
Methyldopa—Nausea—Thiotepa—urinary bladder cancer	0.00101	0.00175	CcSEcCtD
Methyldopa—Agranulocytosis—Epirubicin—urinary bladder cancer	0.001	0.00173	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000994	0.00172	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—urinary bladder cancer	0.000994	0.00172	CcSEcCtD
Methyldopa—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000983	0.0017	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000983	0.00398	CbGpPWpGaD
Methyldopa—Bradycardia—Epirubicin—urinary bladder cancer	0.000982	0.0017	CcSEcCtD
Methyldopa—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00098	0.00169	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000972	0.00393	CbGpPWpGaD
Methyldopa—Jaundice—Doxorubicin—urinary bladder cancer	0.000969	0.00168	CcSEcCtD
Methyldopa—Body temperature increased—Etoposide—urinary bladder cancer	0.000966	0.00167	CcSEcCtD
Methyldopa—Hepatitis—Epirubicin—urinary bladder cancer	0.000965	0.00167	CcSEcCtD
Methyldopa—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000963	0.00166	CcSEcCtD
Methyldopa—Asthenia—Cisplatin—urinary bladder cancer	0.000957	0.00166	CcSEcCtD
Methyldopa—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000957	0.00165	CcSEcCtD
Methyldopa—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000948	0.00164	CcSEcCtD
Methyldopa—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00094	0.00163	CcSEcCtD
Methyldopa—Angiopathy—Methotrexate—urinary bladder cancer	0.000935	0.00162	CcSEcCtD
Methyldopa—Dizziness—Fluorouracil—urinary bladder cancer	0.000931	0.00161	CcSEcCtD
Methyldopa—DDC—Metabolism—GSTZ1—urinary bladder cancer	0.000931	0.00377	CbGpPWpGaD
Methyldopa—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000929	0.00161	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000928	0.0016	CcSEcCtD
Methyldopa—Diarrhoea—Cisplatin—urinary bladder cancer	0.000913	0.00158	CcSEcCtD
Methyldopa—Vomiting—Gemcitabine—urinary bladder cancer	0.00091	0.00157	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—urinary bladder cancer	0.000909	0.00157	CcSEcCtD
Methyldopa—Mental disorder—Methotrexate—urinary bladder cancer	0.000903	0.00156	CcSEcCtD
Methyldopa—Rash—Gemcitabine—urinary bladder cancer	0.000903	0.00156	CcSEcCtD
Methyldopa—Dermatitis—Gemcitabine—urinary bladder cancer	0.000902	0.00156	CcSEcCtD
Methyldopa—Hypersensitivity—Etoposide—urinary bladder cancer	0.000901	0.00156	CcSEcCtD
Methyldopa—Headache—Gemcitabine—urinary bladder cancer	0.000897	0.00155	CcSEcCtD
Methyldopa—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000895	0.00155	CcSEcCtD
Methyldopa—Vomiting—Fluorouracil—urinary bladder cancer	0.000895	0.00155	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—urinary bladder cancer	0.000893	0.00154	CcSEcCtD
Methyldopa—Rash—Fluorouracil—urinary bladder cancer	0.000888	0.00153	CcSEcCtD
Methyldopa—Dermatitis—Fluorouracil—urinary bladder cancer	0.000887	0.00153	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000883	0.00357	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTO2—urinary bladder cancer	0.000882	0.00357	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NAT1—urinary bladder cancer	0.000882	0.00357	CbGpPWpGaD
Methyldopa—Headache—Fluorouracil—urinary bladder cancer	0.000882	0.00152	CcSEcCtD
Methyldopa—Asthenia—Etoposide—urinary bladder cancer	0.000877	0.00152	CcSEcCtD
Methyldopa—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000877	0.00152	CcSEcCtD
Methyldopa—Angiopathy—Epirubicin—urinary bladder cancer	0.000875	0.00151	CcSEcCtD
Methyldopa—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000869	0.0015	CcSEcCtD
Methyldopa—Nausea—Gemcitabine—urinary bladder cancer	0.00085	0.00147	CcSEcCtD
Methyldopa—Vomiting—Cisplatin—urinary bladder cancer	0.000848	0.00147	CcSEcCtD
Methyldopa—Mental disorder—Epirubicin—urinary bladder cancer	0.000845	0.00146	CcSEcCtD
Methyldopa—Rash—Cisplatin—urinary bladder cancer	0.000841	0.00145	CcSEcCtD
Methyldopa—Dermatitis—Cisplatin—urinary bladder cancer	0.000841	0.00145	CcSEcCtD
Methyldopa—Diarrhoea—Etoposide—urinary bladder cancer	0.000836	0.00145	CcSEcCtD
Methyldopa—Nausea—Fluorouracil—urinary bladder cancer	0.000836	0.00145	CcSEcCtD
Methyldopa—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000828	0.00143	CcSEcCtD
Methyldopa—Flatulence—Epirubicin—urinary bladder cancer	0.000827	0.00143	CcSEcCtD
Methyldopa—COMT—Metabolism—GSTZ1—urinary bladder cancer	0.000826	0.00334	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000825	0.00334	CbGpPWpGaD
Methyldopa—Angiopathy—Doxorubicin—urinary bladder cancer	0.00081	0.0014	CcSEcCtD
Methyldopa—Dizziness—Etoposide—urinary bladder cancer	0.000808	0.0014	CcSEcCtD
Methyldopa—DDC—Metabolism—UGT2B7—urinary bladder cancer	0.000807	0.00327	CbGpPWpGaD
Methyldopa—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000804	0.00139	CcSEcCtD
Methyldopa—Leukopenia—Methotrexate—urinary bladder cancer	0.000803	0.00139	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000801	0.00324	CbGpPWpGaD
Methyldopa—Nausea—Cisplatin—urinary bladder cancer	0.000793	0.00137	CcSEcCtD
Methyldopa—COMT—Metabolism—GSTO2—urinary bladder cancer	0.000783	0.00317	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NAT1—urinary bladder cancer	0.000783	0.00317	CbGpPWpGaD
Methyldopa—Mental disorder—Doxorubicin—urinary bladder cancer	0.000782	0.00135	CcSEcCtD
Methyldopa—Vomiting—Etoposide—urinary bladder cancer	0.000777	0.00134	CcSEcCtD
Methyldopa—Rash—Etoposide—urinary bladder cancer	0.000771	0.00133	CcSEcCtD
Methyldopa—Dermatitis—Etoposide—urinary bladder cancer	0.00077	0.00133	CcSEcCtD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—SRC—urinary bladder cancer	0.000768	0.00311	CbGpPWpGaD
Methyldopa—Headache—Etoposide—urinary bladder cancer	0.000766	0.00132	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—urinary bladder cancer	0.000766	0.00132	CcSEcCtD
Methyldopa—Arthralgia—Methotrexate—urinary bladder cancer	0.000764	0.00132	CcSEcCtD
Methyldopa—Myalgia—Methotrexate—urinary bladder cancer	0.000764	0.00132	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000759	0.00131	CcSEcCtD
Methyldopa—Leukopenia—Epirubicin—urinary bladder cancer	0.000752	0.0013	CcSEcCtD
Methyldopa—Infection—Methotrexate—urinary bladder cancer	0.000728	0.00126	CcSEcCtD
Methyldopa—DDC—Metabolism—CYP4B1—urinary bladder cancer	0.000726	0.00294	CbGpPWpGaD
Methyldopa—Nausea—Etoposide—urinary bladder cancer	0.000726	0.00126	CcSEcCtD
Methyldopa—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000718	0.00124	CcSEcCtD
Methyldopa—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000717	0.00124	CcSEcCtD
Methyldopa—COMT—Metabolism—UGT2B7—urinary bladder cancer	0.000716	0.0029	CbGpPWpGaD
Methyldopa—Arthralgia—Epirubicin—urinary bladder cancer	0.000715	0.00124	CcSEcCtD
Methyldopa—Myalgia—Epirubicin—urinary bladder cancer	0.000715	0.00124	CcSEcCtD
Methyldopa—Skin disorder—Methotrexate—urinary bladder cancer	0.000711	0.00123	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00071	0.00123	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000708	0.00286	CbGpPWpGaD
Methyldopa—Leukopenia—Doxorubicin—urinary bladder cancer	0.000695	0.0012	CcSEcCtD
Methyldopa—DDC—Metabolism—SLC19A1—urinary bladder cancer	0.000686	0.00278	CbGpPWpGaD
Methyldopa—Oedema—Epirubicin—urinary bladder cancer	0.000685	0.00118	CcSEcCtD
Methyldopa—Infection—Epirubicin—urinary bladder cancer	0.000681	0.00118	CcSEcCtD
Methyldopa—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000672	0.00116	CcSEcCtD
Methyldopa—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000671	0.00116	CcSEcCtD
Methyldopa—DDC—Metabolism—PRSS3—urinary bladder cancer	0.000669	0.00271	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000667	0.00115	CcSEcCtD
Methyldopa—Skin disorder—Epirubicin—urinary bladder cancer	0.000666	0.00115	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—urinary bladder cancer	0.000661	0.00114	CcSEcCtD
Methyldopa—Arthralgia—Doxorubicin—urinary bladder cancer	0.000661	0.00114	CcSEcCtD
Methyldopa—Paraesthesia—Methotrexate—urinary bladder cancer	0.000658	0.00114	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000657	0.00114	CcSEcCtD
Methyldopa—COMT—Metabolism—CYP4B1—urinary bladder cancer	0.000645	0.00261	CbGpPWpGaD
Methyldopa—Oedema—Doxorubicin—urinary bladder cancer	0.000634	0.0011	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000632	0.00109	CcSEcCtD
Methyldopa—Infection—Doxorubicin—urinary bladder cancer	0.00063	0.00109	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000624	0.00108	CcSEcCtD
Methyldopa—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000622	0.00107	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000621	0.00107	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—urinary bladder cancer	0.000616	0.00106	CcSEcCtD
Methyldopa—Paraesthesia—Epirubicin—urinary bladder cancer	0.000615	0.00106	CcSEcCtD
Methyldopa—COMT—Metabolism—SLC19A1—urinary bladder cancer	0.000609	0.00247	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000606	0.00245	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PRSS3—urinary bladder cancer	0.000594	0.0024	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000592	0.00102	CcSEcCtD
Methyldopa—Constipation—Epirubicin—urinary bladder cancer	0.000586	0.00101	CcSEcCtD
Methyldopa—Body temperature increased—Methotrexate—urinary bladder cancer	0.000579	0.001	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—EP300—urinary bladder cancer	0.000578	0.00234	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000578	0.000999	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000574	0.00232	CbGpPWpGaD
Methyldopa—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000569	0.000984	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000547	0.000946	CcSEcCtD
Methyldopa—Constipation—Doxorubicin—urinary bladder cancer	0.000542	0.000937	CcSEcCtD
Methyldopa—Body temperature increased—Epirubicin—urinary bladder cancer	0.000542	0.000936	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000541	0.00219	CbGpPWpGaD
Methyldopa—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00054	0.000933	CcSEcCtD
Methyldopa—DDC—Metabolism—TYMP—urinary bladder cancer	0.000534	0.00216	CbGpPWpGaD
Methyldopa—Asthenia—Methotrexate—urinary bladder cancer	0.000525	0.000908	CcSEcCtD
Methyldopa—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000505	0.000873	CcSEcCtD
Methyldopa—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000501	0.000866	CcSEcCtD
Methyldopa—Diarrhoea—Methotrexate—urinary bladder cancer	0.000501	0.000866	CcSEcCtD
Methyldopa—Asthenia—Epirubicin—urinary bladder cancer	0.000492	0.00085	CcSEcCtD
Methyldopa—Dizziness—Methotrexate—urinary bladder cancer	0.000484	0.000837	CcSEcCtD
Methyldopa—DDC—Metabolism—NAT2—urinary bladder cancer	0.000483	0.00196	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TYMP—urinary bladder cancer	0.000475	0.00192	CbGpPWpGaD
Methyldopa—Diarrhoea—Epirubicin—urinary bladder cancer	0.000469	0.000811	CcSEcCtD
Methyldopa—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000467	0.000808	CcSEcCtD
Methyldopa—Vomiting—Methotrexate—urinary bladder cancer	0.000466	0.000805	CcSEcCtD
Methyldopa—Rash—Methotrexate—urinary bladder cancer	0.000462	0.000798	CcSEcCtD
Methyldopa—Dermatitis—Methotrexate—urinary bladder cancer	0.000461	0.000797	CcSEcCtD
Methyldopa—Headache—Methotrexate—urinary bladder cancer	0.000459	0.000793	CcSEcCtD
Methyldopa—Asthenia—Doxorubicin—urinary bladder cancer	0.000455	0.000786	CcSEcCtD
Methyldopa—Dizziness—Epirubicin—urinary bladder cancer	0.000453	0.000783	CcSEcCtD
Methyldopa—Vomiting—Epirubicin—urinary bladder cancer	0.000436	0.000753	CcSEcCtD
Methyldopa—Nausea—Methotrexate—urinary bladder cancer	0.000435	0.000752	CcSEcCtD
Methyldopa—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000434	0.00075	CcSEcCtD
Methyldopa—Rash—Epirubicin—urinary bladder cancer	0.000432	0.000747	CcSEcCtD
Methyldopa—Dermatitis—Epirubicin—urinary bladder cancer	0.000432	0.000746	CcSEcCtD
Methyldopa—Headache—Epirubicin—urinary bladder cancer	0.000429	0.000742	CcSEcCtD
Methyldopa—COMT—Metabolism—NAT2—urinary bladder cancer	0.000429	0.00174	CbGpPWpGaD
Methyldopa—Dizziness—Doxorubicin—urinary bladder cancer	0.000419	0.000725	CcSEcCtD
Methyldopa—DDC—Metabolism—RRM2—urinary bladder cancer	0.000417	0.00169	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TP53—urinary bladder cancer	0.000413	0.00167	CbGpPWpGaD
Methyldopa—Nausea—Epirubicin—urinary bladder cancer	0.000407	0.000704	CcSEcCtD
Methyldopa—Vomiting—Doxorubicin—urinary bladder cancer	0.000403	0.000697	CcSEcCtD
Methyldopa—Rash—Doxorubicin—urinary bladder cancer	0.0004	0.000691	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—urinary bladder cancer	0.000399	0.00069	CcSEcCtD
Methyldopa—Headache—Doxorubicin—urinary bladder cancer	0.000397	0.000687	CcSEcCtD
Methyldopa—DDC—Metabolism—ENO2—urinary bladder cancer	0.000386	0.00156	CbGpPWpGaD
Methyldopa—DDC—Metabolism—HPGDS—urinary bladder cancer	0.000386	0.00156	CbGpPWpGaD
Methyldopa—Nausea—Doxorubicin—urinary bladder cancer	0.000377	0.000651	CcSEcCtD
Methyldopa—DDC—Metabolism—GSTT1—urinary bladder cancer	0.000375	0.00152	CbGpPWpGaD
Methyldopa—COMT—Metabolism—RRM2—urinary bladder cancer	0.00037	0.0015	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000353	0.00143	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ENO2—urinary bladder cancer	0.000343	0.00139	CbGpPWpGaD
Methyldopa—COMT—Metabolism—HPGDS—urinary bladder cancer	0.000343	0.00139	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTT1—urinary bladder cancer	0.000333	0.00135	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTZ1—urinary bladder cancer	0.000328	0.00133	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NQO1—urinary bladder cancer	0.000311	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NAT1—urinary bladder cancer	0.000311	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTO2—urinary bladder cancer	0.000311	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—UGT2B7—urinary bladder cancer	0.000285	0.00115	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NQO1—urinary bladder cancer	0.000277	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	0.000274	0.00111	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—HRAS—urinary bladder cancer	0.00027	0.00109	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTP1—urinary bladder cancer	0.00026	0.00105	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP4B1—urinary bladder cancer	0.000256	0.00104	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000253	0.00102	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.000251	0.00102	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNA2—urinary bladder cancer	0.000244	0.000989	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC19A1—urinary bladder cancer	0.000242	0.00098	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TYMS—urinary bladder cancer	0.000242	0.000977	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTM1—urinary bladder cancer	0.000239	0.000966	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NCOR1—urinary bladder cancer	0.000239	0.000966	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PRSS3—urinary bladder cancer	0.000236	0.000955	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTP1—urinary bladder cancer	0.000231	0.000934	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GPX1—urinary bladder cancer	0.000229	0.000925	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ERCC2—urinary bladder cancer	0.000224	0.000908	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TYMS—urinary bladder cancer	0.000214	0.000868	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NCOR1—urinary bladder cancer	0.000212	0.000858	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTM1—urinary bladder cancer	0.000212	0.000858	CbGpPWpGaD
Methyldopa—DDC—Metabolism—MTHFR—urinary bladder cancer	0.000211	0.000854	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	0.000211	0.000852	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.00021	0.000849	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GPX1—urinary bladder cancer	0.000203	0.000822	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ERCC2—urinary bladder cancer	0.000199	0.000807	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TYMP—urinary bladder cancer	0.000189	0.000763	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC4—urinary bladder cancer	0.000188	0.000762	CbGpPWpGaD
Methyldopa—COMT—Metabolism—MTHFR—urinary bladder cancer	0.000187	0.000758	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	0.000184	0.000744	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLAU—urinary bladder cancer	0.000173	0.000702	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPARG—urinary bladder cancer	0.000171	0.000692	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NAT2—urinary bladder cancer	0.000171	0.00069	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000167	0.000675	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CREBBP—urinary bladder cancer	0.000164	0.000665	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLI1—urinary bladder cancer	0.000158	0.000638	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARG—urinary bladder cancer	0.000152	0.000615	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—RRM2—urinary bladder cancer	0.000147	0.000596	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CREBBP—urinary bladder cancer	0.000146	0.000591	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CREBBP—urinary bladder cancer	0.000143	0.000579	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF1—urinary bladder cancer	0.000141	0.000572	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HPGDS—urinary bladder cancer	0.000136	0.000552	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO2—urinary bladder cancer	0.000136	0.000552	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—urinary bladder cancer	0.000135	0.000545	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—urinary bladder cancer	0.000132	0.000535	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RHOA—urinary bladder cancer	0.000129	0.000524	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000127	0.000514	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—urinary bladder cancer	0.000119	0.000484	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—urinary bladder cancer	0.000117	0.000475	CbGpPWpGaD
Methyldopa—DDC—Metabolism—EP300—urinary bladder cancer	0.000112	0.000453	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NQO1—urinary bladder cancer	0.00011	0.000445	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—urinary bladder cancer	0.000109	0.000439	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RBX1—urinary bladder cancer	0.000108	0.000437	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—urinary bladder cancer	0.000104	0.000422	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TSC1—urinary bladder cancer	0.000102	0.000411	CbGpPWpGaD
Methyldopa—COMT—Metabolism—EP300—urinary bladder cancer	9.94e-05	0.000402	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EP300—urinary bladder cancer	9.74e-05	0.000394	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAG1—urinary bladder cancer	9.67e-05	0.000392	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SRC—urinary bladder cancer	9.47e-05	0.000383	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTP1—urinary bladder cancer	9.17e-05	0.000371	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TYMS—urinary bladder cancer	8.52e-05	0.000345	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—urinary bladder cancer	8.42e-05	0.000341	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOR1—urinary bladder cancer	8.42e-05	0.000341	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	8.18e-05	0.000331	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPX1—urinary bladder cancer	8.07e-05	0.000326	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ERCC2—urinary bladder cancer	7.92e-05	0.000321	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—urinary bladder cancer	7.84e-05	0.000317	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—S100B—urinary bladder cancer	7.83e-05	0.000317	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—urinary bladder cancer	7.44e-05	0.000301	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RHOA—urinary bladder cancer	7.43e-05	0.000301	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.18e-05	0.000291	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	7.04e-05	0.000285	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—urinary bladder cancer	6.97e-05	0.000282	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	6.86e-05	0.000278	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	6.67e-05	0.00027	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	6.52e-05	0.000264	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	6.23e-05	0.000252	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	6.21e-05	0.000251	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARG—urinary bladder cancer	6.04e-05	0.000244	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	5.8e-05	0.000235	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	5.7e-05	0.000231	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	5.53e-05	0.000224	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	4.85e-05	0.000196	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	4.79e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	4.77e-05	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	4.75e-05	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	4.5e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	4.39e-05	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—urinary bladder cancer	4.14e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	4.06e-05	0.000164	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—EP300—urinary bladder cancer	3.95e-05	0.00016	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	3.85e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	3.83e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	3.68e-05	0.000149	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	3.59e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	3.48e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	3.47e-05	0.00014	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	3.46e-05	0.00014	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	3.3e-05	0.000134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	3.21e-05	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	2.88e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	2.81e-05	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	2.66e-05	0.000108	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	2.36e-05	9.57e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	2.26e-05	9.15e-05	CbGpPWpGaD
